7 results about "Respiratory chain" patented technology

The construction and application of an intratumorally self-proliferating enhanced oncolytic microbial delivery system belongs to the field of pharmaceutical formulation technology. Through a synthetic reaction, a hydrogen sulfide donor is endowed with a membrane-intercalable regional structure. Then, a lipid membrane containing the membrane-intercalable hydrogen sulfide donor is used to encapsulate bacteria through self-assembly, thus preparing an intratumorally self-proliferating enhanced oncolytic microbial delivery system. After intravenous injection of the delivery system, it accumulates within the tumor. In the tumor inflammatory microenvironment, the hydrogen sulfide released by the donor can be converted into tetrathionate. Tetrathionate respiration is a unique form of respiration in Salmonella. Through both aerobic and tetrathionate respiration, the system specifically promotes the proliferation of Salmonella in the tumor site, thereby enhancing tumor cell pyroptosis and achieving anti-tumor effects. This invention provides a novel theory and advanced solution for cancer treatment, and also offers promising strategies and exploratory ideas for the clinical application of attenuated Salmonella, possessing significant scientific research value.

The invention belongs to the field of biology, and discloses a tissue formula preserving fluid containing antimycin A. The tissue formula preserving fluid comprises a basic culture medium, the basal culture medium contains superoxide dismutase, catalase and antimycin A. On the basis of the superoxide dismutase and the catalase, the preservation solution is matched with the antimycin A, so that the activity of tissue cells can be remarkably improved; in the research process, we have the following specificity that: 1, when the respiratory chain inhibitor drug is applied to the formula of the invention, the improvement degree of the cell viability of only antimycin A is the highest; 2, the function of antimycin A must be exerted based on the use of superoxide dismutase and catalase; meanwhile, the invention further provides a tissue preservation method.

This invention belongs to the field of biomedical technology, specifically relating to compounds for treating KRAS-mutant tumors and their uses. This invention provides compound 666-15, which provides dual inhibition of cytoplasmic-mitochondrial NAD5. + Transport (via targeting SLC25A51) and succinate dehydrogenase (SDH / complex II), while simultaneously disrupting mitochondrial NAD. + Transport and respiratory chain NAD + A novel therapeutic strategy to target KRAS-mutant tumors by utilizing regenerative functions.

The application discloses a Parkinson's disease targeted application of a pueraria exosome loaded with a mitochondria-activated miRNA, and belongs to the field of biological applications.The miRNA comprises at least one of miRNAs shown in sequences as shown in SEQ ID No, 1 to SEQ ID No, 23.The pueraria exosome and the miRNA delivered thereby in the application show a good treatment effect on Parkinson's disease, and mainly play a role in improving mitochondrial dysfunction, such as promoting mitochondrial autophagy, improving mitochondrial membrane potential, reducing oxidative stress, maintaining the integrity of the mitochondrial inner membrane respiratory chain, and increasing ATP generation.The application further discloses a delivery scheme of the pueraria-derived exosome as the miRNA carrier by using neuron-targeted modification, which can improve the targeting and stability of the miRNA, and overcome the problems of low miRNA drug delivery efficiency and easy degradation.The application is expected to promote the treatment process of Parkinson's disease through the neuron-targeted pueraria exosome and the miRNA delivered thereby.

The invention discloses rhodococcus capable of improving eggshell quality, uterine tissue damage and energy metabolism of old laying hens and application of the rhodococcus. The invention belongs to the field of microorganisms, and particularly relates to rhodococcus capable of improving eggshell quality, uterine tissue damage and energy metabolism of old laying hens and application of the rhodococcus. The Rhodococcus ruber disclosed by the invention is Rhodococcus ruber NML-01, and the registration number of the Rhodococcus ruber NML-01 in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms is CGMCC No.36760. The NML-01 strain can effectively increase the eggshell thickness of old laying hens, contributes to reducing the egg breaking rate and prolonging the egg laying cycle and economic utilization period of the laying hens, can reduce oxidative stress (MDA) and DNA damage (rH2AX) of uterine tissues, activates mitochondrial autophagy by up-regulating a PINK1 / PARK pathway, and improves the respiratory chain complex IV activity and ATP level.

This invention discloses a method for producing ethanol by fermentation of Saccharomyces cerevisiae based on a dual antimicrobial strategy. The method involves inhibiting the respiratory chain of contaminating microorganisms with cyanamide and utilizing the overexpression of the gene encoding cyanamide hydratase in Saccharomyces cerevisiae 1308. CAH To reduce the impact of cyanamide on Saccharomyces cerevisiae, this invention employs the antimicrobial peptide DptB and the endolysin LysKB317 to target and inhibit Acetobacter and Lactobacillus. This invention combines the chemical antimicrobial properties of cyanamide with the biological antimicrobial properties of the endolysin, forming a dual antimicrobial strategy in the fermentation process of Saccharomyces cerevisiae for ethanol production. The synergistic effect of chemical and biological antimicrobial action achieves an organic combination of broad-spectrum and targeted antimicrobial activity. This effectively inhibits contaminating bacteria while reducing interference with Saccharomyces cerevisiae metabolism caused by chemical antimicrobial agents, thus lowering the risk of contamination during industrial ethanol production. Ultimately, it improves the stability and economic efficiency of ethanol production, increasing the ethanol yield of the 50–200 g / L glucose fermentation system by 10.1%–23.7% compared to the control group.

The invention discloses a cell factory for efficiently producing squalene, which is characterized in that a squalene engineering strain SquMC13 with'cytoplasm-mitochondria 'dual regulation and control in a laboratory is taken as an original strain, a plurality of modification strategies associated with relieving Crab tree are tried, and a plurality of saccharomyces cerevisiae gene engineering strains are screened from the original strain and comprise saccharomyces cerevisiae gene engineering strains C12, C15, C34, C41 and C46; wherein the squalene production capacity of the saccharomyces cerevisiae genetic engineering strain C46 is most prominent, and the squalene yield fermented by a 5-liter bioreactor is up to 57.21 g / L. According to the gene modification disclosed by the invention, the carbon flow is promoted to enter a respiratory chain and TCA circulation, and meanwhile, the metabolism steady state of cells is effectively improved by means of mitochondrial function enhancement, cell robustness improvement and the like, so that a new technical approach is provided for realizing efficient production of squalene under industrial conditions.